AI comes to the Nobel Prize and drug discovery

Ying Zhou; Yintao Zhang; Zhichao Zhang; Zhimeng Zhou; Feng Zhu

doi:10.1016/j.jpha.2024.101160

Volume 14 Issue 11

Nov. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2024 > 14(11): 101160

Ying Zhou, Yintao Zhang, Zhichao Zhang, Zhimeng Zhou, Feng Zhu. AI comes to the Nobel Prize and drug discovery[J]. Journal of Pharmaceutical Analysis, 2024, 14(11): 101160. doi: 10.1016/j.jpha.2024.101160

Citation:

Ying Zhou, Yintao Zhang, Zhichao Zhang, Zhimeng Zhou, Feng Zhu. AI comes to the Nobel Prize and drug discovery[J]. Journal of Pharmaceutical Analysis, 2024, 14(11): 101160. doi: 10.1016/j.jpha.2024.101160

Citation:

PDF( 792 KB)

AI comes to the Nobel Prize and drug discovery

doi: 10.1016/j.jpha.2024.101160

1. College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China;
2. College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China;
3. Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Hangzhou, 330110, China

Funds:

This study is funded by National Natural Science Foundation of China of China (Grant Nos.: 82373790, 22220102001, 81872798, and U1909208), Natural Science Foundation of Zhejiang Province (Grant No.: RG25H300001, LR21H300001), Fundamental Research Funds for the Central Universities (Grant No.: 2018QNA7023), National Key R&D Program of China (Grant No.: 2022YFC3400501), and Double Top-Class University (Grant No.: 181201^*194232101).

Available Online: Dec. 26, 2024

Abstract

FullText(HTML)

References(10)

References

[1]	M. Lu, J. Yin, Q. Zhu, et al. Artificial intelligence in pharmaceutical sciences, Engineering 27 (2023) 37-69.
[2]	Y. Zhou, Y. Zhang, D. Zhao, et al., TTD: Therapeutic Target Database describing target druggability information, Nucleic Acids Res. 52 (2024) D1465-D1477.
[3]	F. Li, M. Mou, X. Li, et al., DrugMAP 2.0: Molecular atlas and pharma-information of all drugs, Nucleic Acids Res. (2024), gkae791.
[4]	F. Ren, A. Aliper, J. Chen, et al., A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models, Nat. Biotechnol. (2024) doi: 10.1038/s41587-024-02143-0.
[5]	R.Luo, L. Sun, Y. Xia, et al., BioGPT: Generative pre-trained transformer for biomedical text generation and mining, Brief. Bioinform. 23 (2022), bbac409.
[6]	Y. Li, L. Zhang, Y. Wang, et al., Generative deep learning enables the discovery of a potent and selective RIPK1 inhibitor, Nat. Commun. 13 (2022), 6891.
[7]	H. He, B. He, L. Guan, et al., De novo generation of SARS-CoV-2 antibody CDRH3 with a pre-trained generative large language model, Nat Commun. 15 (2024), 6867.
[8]	S.J. Gosai, R.I. Castro, N. Fuentes, et al., Machine-guided design of cell-type-targeting cis-regulatory elements, Nature 634 (2024) 1211-1220.
[9]	H. Zhang, L. Zhang, A. Lin, et al., Algorithm for optimized mRNA design improves stability and immunogenicity, Nature 621 (2023) 396-403.
[10]	J. Jimenez-Luna, F. Grisoni, G. Schneider, Drug discovery with explainable artificial intelligence. Nat Mach Intell. 2 (2020) 573-584.